Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Change in Cash (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Change in Cash for 9 consecutive years, with -$176.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash changed N/A to -$176.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$17.8 million, a N/A change, with the full-year FY2025 number at -$17.8 million, up 78.2% from a year prior.
  • Change in Cash was -$176.6 million for Q4 2025 at Soleno Therapeutics, down from $170.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $170.2 million in Q3 2025 to a low of -$176.6 million in Q4 2025.